Finding. Most pathogenic Mitofusin 2 (MFN2) variants cause Charcot-Marie-Tooth type 2A (CMT2A), a peripheral neuropathy. A small set also hits the central nervous system and causes cerebellar ataxia. Zaman, Shutt and colleagues give that split a mechanism. Ataxia-linked MFN2 variants raise ferroptosis sensitivity. They act as a gain-of-function: more fatty acid moves from lipid droplets into mitochondria, the lipidome changes, and cells are primed for lipid peroxidation. Ferroptosis is already on the books for Friedreich ataxia. The authors argue that this, not the usual fusion failure, is why these alleles make ataxia.
Why this paper matters
MFN2 is taught as a fusion GTPase. That story explains why mitochondria fragment and why axons fail. It does not explain why a minority of families get a cerebellar disease. A lipid-droplet/mitochondrial fatty-acid axis does. It also gives drug hunters a different lever: ferroptosis and lipolysis, not only fusion agonists.
The Friedreich parallel is the sentence clinicians will remember. Two ataxia genes, two mitochondrial iron/lipid problems, one death path.
How to read the score
Ninety. Human disease genetics, a gain-of-function (not another loss-of-fusion), a lipid-droplet handle, and a testable death pathway. Confidence is high for the correlation as stated. It is medium for "this is why the cerebellum dies."
Caveats
We are on the abstract. The variant table, the cell system, and the ferroptosis recipe are in the PDF. Gain-of-function on import needs a trafficking measurement. Cerebellar ataxia is not proven by a dish assay. Do not tell a CMT2A family this is their mechanism.
What to do with it
If you curate MFN2, tag ataxia alleles separately and attach ferroptosis and lipidomics. If you model mitofusin lipids, measure droplet-to-mitochondrion fatty-acid flux, not only endoplasmic reticulum contacts. Compare to Friedreich before you compare to generic CMT.